Comparison of user-friendliness and treatment cost of Loceryl®vs. Ciclopoli®- a patient's perspective

Autor:	J Muller, Martin Schaller, Christina Braunsdorf, Daniela Mailänder-Sánchez, Claudia Borelli, Andreas Jäckel
Rok vydání:	2015
Předmět:	Adult Male medicine.medical_specialty Antifungal Agents Pyridones Administration Topical Morpholines Dermatology User friendliness Patient satisfaction Germany Surveys and Questionnaires Onychomycosis Amorolfine medicine Humans Prospective Studies Treatment costs Foot Dermatoses Ciclopirox business.industry Treatment regimen Topical antifungal Health Care Costs General Medicine Treatment period Surgery Infectious Diseases Nails Patient Satisfaction business medicine.drug
Zdroj:	Mycoses. 58:632-636
ISSN:	0933-7407
DOI:	10.1111/myc.12371
Popis:	Topical monotherapy is a valid therapeutic approach in onychomycosis. Due to its lengthy course and its non-reimbursed product status, cost and compliance are important issues and non-pharmacological properties such as over-the-counter price and ease of use should be considered when deciding which product to recommend. We investigated surrogate parameters for patient-friendliness and treatment cost in Germany in a questionnaire-based prospective, comparative, intra-individual, open-label trial of the two common topical antifungal nail lacquers Loceryl(®) (amorolfine 5%) and Ciclopoli(®) (ciclopirox 8%) in eight patients with clinically diagnosed onychomycosis. The 2.5 ml bottle of Loceryl(®) covered a treatment period of 308 days, resulting in treatment costs of €0.10 per day in comparison to the 3.3 ml bottle of Ciclopoli(®), covering 127 days at €0.21 per day, given once-daily application for Ciclopoli(®) and once-weekly application for Loceryl(®) in accordance with regulatory approval. Six out of eight patients favoured the Loceryl(®) treatment regimen. Furthermore, four out of eight patients found Loceryl(®) easier to apply, whereas three preferred Ciclopoli(®). In total, seven out of eight stated a clear preference for Loceryl(®) over Ciclopoli(®). Loceryl(®) therapy is less expensive and less time-consuming. The therapeutic period that can be covered is longer and more patients stated a clear preference for Loceryl(®) in comparison to Ciclopoli(®). The differences are statistically significant, underlining probable clinical relevance.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c34c9a0eaa12e3530cfe86dc9ba6134 https://doi.org/10.1111/myc.12371 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.